@article{03fbb861289b4dff8635943fe6695b4e,
title = "Targeting glycans for CAR therapy: The advent of sweet CARs",
abstract = "Chimeric antigen receptor (CAR) T cell therapy has created a paradigm shift in the treatment of hematologic malignancies but has not been as effective toward solid tumors. For such tumors, the primary obstacles facing CAR T cells are scarcity of tumor-specific antigens and the hostile and complex tumor microenvironment. Glycosylation, the process by which sugars are post-translationally added to proteins or lipids, is profoundly dysregulated in cancer. Abnormally glycosylated glycoproteins expressed on cancer cells offer unique targets for CAR T therapy as they are specific to tumor cells. Tumor stromal cells also express abnormal glycoproteins and thus also have the potential to be targeted by glycan-binding CAR T cells. This review will discuss the state of CAR T cells in the therapy of solid tumors, the cancer glycoproteome and its potential for use as a therapeutic target, and the landscape and future of glycan-binding CAR T cell therapy.",
keywords = "CAR T cell therapy, cancer glycobiology, glycan, glycoprotein, solid tumor, tumor microenvironment, Immunotherapy, Adoptive, Humans, Tumor Microenvironment, Glycoproteins, Neoplasms, Polysaccharides, Receptors, Antigen, T-Cell/metabolism",
author = "Zoe Raglow and McKenna, {Mary Kathryn} and Bonifant, {Challice L.} and Wenjing Wang and {Pasca di Magliano}, Marina and Johannes Stadlmann and Penninger, {Josef M.} and Cummings, {Richard D.} and Brenner, {Malcolm K.} and Markovitz, {David M.}",
note = "Funding Information: M.K.M. is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award number 5T32HL092332-17 supervised by Dr. Helen Heslop and the National Cancer Institute under the award 5PO1CA094237-15. C.L.B. is a St. Baldrick's Foundation Scholar, has pending patent applications describing the use of engineered T and NK cells to enhance tumor targeting, including the use of H84T-BanLec effector cell targeting of SARS-CoV-2, and has received research funding from Merck, Sharp, and Dohme, Inc., Kiadis Pharma, and Bristol Myers Squibb. W.W. is supported by the University of Michigan. M.P.d.M. is supported by National Cancer Institute grant U01-CA224145 and NIH grants R01-CA271510 and R01-CA224145. J.M.P. is supported by a Canada 150 Chair and the T. von Zastrow Foundation. R.D.C. is supported by NIH grant R01GM140201. M.K.B. is supported by National Cancer Institute grant nos. P50CA126752 and P01CA094237, by Stand Up To Cancer (SU2C)/American Association for Cancer Research (AACR) 604817 Meg Vosburg T-Cell Lymphoma Dream Team, and the Leukemia and Lymphoma Society. SU2C is a program of the Entertainment Industry Foundation administered by the AACR. M.K.B. is a co-founder with equity at Tessa Therapeutics and Marker Therapeutics and is on the scientific advisory boards for Bluebird Bio, Turnstone, Tessa Therapeutics, Marker Therapeutics, Allogene, Walking Fish, Memgen, KUUR, Bellicum Pharmaceuticals, Tscan, Poseida, and Abintus. D.M.M. was supported by a grant from the Forbes Institute of the Rogel Cancer Center at the University of Michigan and is an inventor on University of Michigan patents concerning H84T BanLec. Figures 1 and 2 and the graphical abstract were created with BioRender.com. The authors declare no competing interests. Funding Information: M.K.M. is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award number 5T32HL092332-17 supervised by Dr. Helen Heslop and the National Cancer Institute under the award 5PO1CA094237-15 . C.L.B. is a St. Baldrick{\textquoteright}s Foundation Scholar, has pending patent applications describing the use of engineered T and NK cells to enhance tumor targeting, including the use of H84T-BanLec effector cell targeting of SARS-CoV-2, and has received research funding from Merck , Sharp , and Dohme, Inc. , Kiadis Pharma , and Bristol Myers Squibb . W.W. is supported by the University of Michigan . M.P.d.M. is supported by National Cancer Institute grant U01-CA224145 and NIH grants R01-CA271510 and R01-CA224145 . J.M.P. is supported by a Canada 150 Chair and the T. von Zastrow Foundation . R.D.C. is supported by NIH grant R01GM140201 . M.K.B. is supported by National Cancer Institute grant nos. P50CA126752 and P01CA094237 , by Stand Up To Cancer (SU2C)/ American Association for Cancer Research (AACR) 604817 Meg Vosburg T-Cell Lymphoma Dream Team, and the Leukemia and Lymphoma Society. SU2C is a program of the Entertainment Industry Foundation administered by the AACR. M.K.B. is a co-founder with equity at Tessa Therapeutics and Marker Therapeutics and is on the scientific advisory boards for Bluebird Bio, Turnstone, Tessa Therapeutics, Marker Therapeutics, Allogene, Walking Fish, Memgen, KUUR, Bellicum Pharmaceuticals, Tscan, Poseida, and Abintus. D.M.M. was supported by a grant from the Forbes Institute of the Rogel Cancer Center at the University of Michigan and is an inventor on University of Michigan patents concerning H84T BanLec. Figures 1 and 2 and the graphical abstract were created with BioRender.com . Publisher Copyright: {\textcopyright} 2022 The American Society of Gene and Cell Therapy",
year = "2022",
month = sep,
day = "7",
doi = "10.1016/j.ymthe.2022.07.006",
language = "English (US)",
volume = "30",
pages = "2881--2890",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "9",
}